

Giulia Ceglie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4372130/publications.pdf>

Version: 2024-02-01

16
papers

193
citations

1163117

8
h-index

1199594

12
g-index

17
all docs

17
docs citations

17
times ranked

381
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune thrombocytopenia in a child with COVID-19: Is it the calm after the (cytokine) storm?. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29326.	1.5	7
2	Brentuximab vedotin as a single agent in the treatment of a pediatric primary cutaneous CD30 ⁺ lymphoproliferative disorder: A case report. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29626.	1.5	0
3	Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells. <i>British Journal of Haematology</i> , 2022, 197, 110-119.	2.5	10
4	Immune thrombocytopenia in two infant cases managed with eltrombopag. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29120.	1.5	1
5	Hematopoietic Stem Cell Transplantation in Neuromyelitis Optica-Spectrum Disorders (NMO-SD): State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5304.	4.1	22
6	Infantile/Congenital High-Grade Gliomas: Molecular Features and Therapeutic Perspectives. <i>Diagnostics</i> , 2020, 10, 648.	2.6	15
7	Scurvy: still a threat in the well-fed first world?. <i>Archives of Disease in Childhood</i> , 2019, 104, 381-383.	1.9	29
8	TMOD-14. INNOVATIVE 3D MODEL FOR THE ESTABLISHMENT OF PRIMARY PAEDIATRIC LOW-GRADE GLIOMA (LGG) CULTURES: NEW PLATFORM FOR ADVANCED PRECLINICAL STUDIES OF INNOVATIVE AND IMMUNOTHERAPEUTIC APPROACHES. <i>Neuro-Oncology</i> , 2019, 21, ii123-ii124.	1.2	0
9	T-cell depleted HLA-haploidentical HSCT in a child with neuromyelitis optica. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2110-2113.	3.7	11
10	Vemurafenib Treatment of Pleomorphic Xanthoastrocytoma in a Child With Down Syndrome. <i>Frontiers in Oncology</i> , 2019, 9, 277.	2.8	10
11	Unusual cause of dyspnoea. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2018, 103, edpract-2017-313059.	0.5	0
12	BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas. <i>Frontiers in Oncology</i> , 2018, 8, 526.	2.8	37
13	Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. <i>Oncotarget</i> , 2016, 7, 13886-13901.	1.8	20
14	A case of lineage switch from B-cell acute lymphoblastic leukaemia to acute myeloid leukaemia. Role of subclonal/clonal gene mutations. <i>British Journal of Haematology</i> , 2016, 174, 648-651.	2.5	7
15	Genomic Characterization of Acute Leukemias. <i>Medical Principles and Practice</i> , 2014, 23, 487-506.	2.4	23
16	Impact of restrictive measures due to the Covid-19 pandemic on the incidence of immune thrombocytopenia in children: an Italian single center experience. <i>Pediatric Hematology and Oncology</i> , 0, , 1-4.	0.8	1